Abstract: Heart failure (HF), a myocardial injury syndrome with multiple etiologies, can result in reduction of ventricle pump function and/or filling ability with hypertension, coronary heart disease, and other cardiovascular pathogenesis. HF is a progressive disease, with high morbidity, a high fatality rate, and high associated medical costs. Unfortunately, at present, there are limited beneficial effects to current therupies. Entresto, which has dual effects on inhibition of both neprilysin and the rennin angiotensin aldosterone system, is a new type of drug utilized to treate HF. The present review aims to summarize pharmacodynamic/pharmacokinetics relationships, clinical efficacy, and the safety of Entresto. Finally, the review provides additional evidence for its clinical application.